ORIGINAL ARTICLE

Changing trends in US mesothelioma incidence

H Weill¹, J M Hughes² and A M Churg³

¹ Department of Medicine, Tulane University School of Medicine, New Orleans, LA, USA
² Department of Biostatistics, Tulane University School of Tropical Medicine and Public Health, New Orleans, LA, USA
³ Department of Pathology, University of British Columbia, Vancouver, BC Canada

Correspondence to:
Correspondence to:
Dr H Weill
755 Hearthstone Drive, Basalt, CO 81621, USA; weill{at}rof.net

Aims: To report the temporal pattern and change in trend of mesothelioma incidence in the United States since 1973.

Methods: The Surveillance, Epidemiology, and End Results (SEER) programme of the National Cancer Institute has since 1973 provided annual age adjusted incidence for mesothelioma in representative cancer registries dispersed throughout the USA. SEER data are analysed to describe the trend of male mesothelioma incidence in the USA.

Results: The US male mesothelioma incidence data indicate that after two decades of increasing incidence, a likely decline has been observed since the early 1990s, when a highly significant change in the upward course occurred.

Conclusions: Increasing male mesothelioma incidence for many years was undoubtedly the result of exposure to asbestos. The high mesothelioma risk was prominently influenced by exposure to amphibole asbestos (crocidolite and amosite), which reached its peak usage in the 1960s and thereafter declined. A differing pattern in some other countries (continuing rise in incidence) may be related to their greater and later amphibole use, particularly crocidolite. The known latency period for the development of this tumour provides biological plausibility for the recent decline in mesothelioma incidence in the USA. This favourable finding is contrary to a widespread fear that asbestos related health effects will show an inevitable increase in coming years, or even decades.

Keywords: mesothelioma; asbestos; cancer trends; SEER

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Tsao, A. S., Wistuba, I., Roth, J. A., Kindler, H. L. (2009). Malignant Pleural Mesothelioma. JCO 27: 2081-2090 [Abstract] [Full Text]  
• Clements, M., Berry, G., Shi, J., Ware, S., Yates, D., Johnson, A. (2007). Projected mesothelioma incidence in men in New South Wales. Occup. Environ. Med. 64: 747-752 [Abstract] [Full Text]  
• Onda, M., Nagata, S., Ho, M., Bera, T. K., Hassan, R., Alexander, R. H., Pastan, I. (2006). Megakaryocyte potentiation factor cleaved from mesothelin precursor is a useful tumor marker in the serum of patients with mesothelioma.. Clin. Cancer Res. 12: 4225-4231 [Abstract] [Full Text]  
• Kanazawa, N., Ioka, A., Tsukuma, H., Ajiki, W., Oshima, A. (2006). Incidence and survival of mesothelioma in osaka, Japan.. Jpn J Clin Oncol 36: 254-257 [Abstract] [Full Text]  
• Pass, H. I., Lott, D., Lonardo, F., Harbut, M., Liu, Z., Tang, N., Carbone, M., Webb, C., Wali, A. (2005). Asbestos exposure, pleural mesothelioma, and serum osteopontin levels.. NEJM 353: 1564-1573 [Abstract] [Full Text]  
• Cullen, M. R. (2005). Serum osteopontin levels--is it time to screen asbestos-exposed workers for pleural mesothelioma?. NEJM 353: 1617-1618 [Full Text]  
• Erasmus, J. J., Truong, M. T., Smythe, W. R., Munden, R. F., Marom, E. M., Rice, D. C., Vaporciyan, A. A., Walsh, G. L., Sabloff, B. S., Broemeling, L. D., Stevens, C. W., Pisters, K. M., Podoloff, D. A., Macapinlac, H. A. (2005). Integrated computed tomography-positron emission tomography in patients with potentially resectable malignant pleural mesothelioma: Staging implications. J. Thorac. Cardiovasc. Surg. 129: 1364-1370 [Abstract] [Full Text]  
• Weill, H, Hughes, J, Churg, A (2005). Changing trends in US mesothelioma incidence. Occup. Environ. Med. 62: 270-270 [Abstract] [Full Text]  
• Greenberg, M (2005). Changing trends in US mesothelioma incidence. Occup. Environ. Med. 62: 134-134 [Full Text]  
• Marcovitch, H. (2004). What's new this month in BMJ Journals. BMJ 328: 1098-1098 [Full Text]